AI Article Synopsis
- Yoga has been shown to promote health and reduce distress, with a focus on its effectiveness in treating substance use disorders through various studies, particularly randomized trials.
- The review discusses how yoga may aid in recovery from substance use disorders by examining the mechanisms of its therapeutic effects.
- It also highlights the implications for clinical practice and addresses challenges in interpreting the findings from existing yoga-related research.
Article Abstract
Yoga has been utilized for promotion of health and alleviating distress. It has also been used as a therapeutic measure in the field of mental health, including substance use disorders. This narrative review discusses the literature pertaining to use of yoga in the treatment of substance use disorders. The evidence base especially with regards to randomized trials is presented. The possible mechanisms how yoga might be helpful in the treatment of substance use disorders are explored. Subsequently, implications of yoga in clinical practice are elaborated, followed by examination of the issues in interpretation of the literature of published yoga related studies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajp.2016.10.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing ADHD prevalence and comorbidities in the United States: Insights from the Substance Abuse and Mental Health Services (SAMHSA) data.
Glob Ment Health (Camb)
December 2024
The Warren Alpert Medical School of Brown University, Providence, RI, USA.
This study analyzes 2022 data from SAMHSA's Mental Health Client-Level Data (MH-CLD) to investigate ADHD prevalence and comorbidity. The findings reveal that 10.70% of the 5,899,698 patients were diagnosed with ADHD, indicating a high demand for targeted resources.
View Article and Find Full Text PDFEthical Considerations Related to Stigma in Mental Health Aspects of Treating Substance Use Disorders.
Focus (Am Psychiatr Publ)
January 2025
Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York.
The Story of the Stop Stigma Together Campaign: A National Movement to Stop the Stigma of Mental and Substance Use Disorders.
Focus (Am Psychiatr Publ)
January 2025
Visionary Leadership, Bethesda, Maryland.
Fumarprotocetraric acid and geraniin were identified as novel inhibitors of human respiratory syncytial virus infection .
Front Cell Infect Microbiol
December 2024
State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Introduction: Respiratory syncytial virus (RSV) remains a major international public health concern. However, disease treatment is limited to preventive care with monoclonal antibodies and supportive care. In this study, natural products were screened to identify novel anti-RSV inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!